FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885063710> ?p ?o ?g. }

• W2885063710 abstract "Previous studies showed that FLT3 inhibitors played an important role in acute myeloid leukemia (AML) therapy. However, discrepancies remain regarding the association between FLT3 inhibitors use and prognosis of AML patients in clinical trials.The aim of this study was to evaluate the effect of FLT3 inhibitors on the treatment of AML in a systematic review and meta-analysis.PubMed, Embase, and Cochrane Library databases were searched for studies published before August 2017 that used FLT3 inhibitors in AML. Fixed- and random-effect models were used, and between-study heterogeneity was assessed.A total of 26 studies fitting our inclusion and exclusion criteria were included. The FLT3 status of patients and main treatment outcomes including overall survival (OS), event-free survival (EFS), relapse-free survival (RFS), complete remission (CR), and overall response rate (ORR) after therapy were extracted. Five studies comparing addition of FLT3 inhibitors and placebo or blank control to chemotherapy were analyzed in Part I, showing improved OS (hazard ratio [HR]=0.86, 95% confidence interval [CI]=0.75-0.99, P=0.03) in the FLT3 inhibitor group but without a significant improvement on EFS (HR=0.86, 95% CI=0.62-1.21, P=0.39) and ORR (odds ratio [OR]=1.10, 95% CI=0.89-1.35, P=0.38). Twenty-one studies evaluating the benefit of using FLT3 inhibitors in different FLT3-type AML patients were analyzed in Part II, showing that FLT3-internal tandem duplication (ITD)-positive patients were more sensitive to FLT3 inhibitor treatment and achieved better CR (OR=1.89, 95% CI=1.06-3.37, P=0.03) and ORR (OR=3.07, 95% CI=2.13-4.43, P<0.001).Our study showed that combined use of FLT3 inhibitors improved OS and that the FLT3 status of AML patients could affect their sensitivity to FLT3 inhibitors in terms of CR and ORR." @default.
• W2885063710 created "2018-08-22" @default.
• W2885063710 creator A5001331259 @default.
• W2885063710 creator A5010293813 @default.
• W2885063710 creator A5034997659 @default.
• W2885063710 creator A5039213269 @default.
• W2885063710 creator A5062418028 @default.
• W2885063710 creator A5077524239 @default.
• W2885063710 creator A5080003280 @default.
• W2885063710 date "2018-08-01" @default.
• W2885063710 modified "2023-09-25" @default.
• W2885063710 title "Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis" @default.
• W2885063710 cites W1504864970 @default.
• W2885063710 cites W1974674483 @default.
• W2885063710 cites W1981811959 @default.
• W2885063710 cites W1984209370 @default.
• W2885063710 cites W1985522609 @default.
• W2885063710 cites W1991687104 @default.
• W2885063710 cites W1993300766 @default.
• W2885063710 cites W2003424912 @default.
• W2885063710 cites W2016883830 @default.
• W2885063710 cites W2024162263 @default.
• W2885063710 cites W2038824910 @default.
• W2885063710 cites W2070609585 @default.
• W2885063710 cites W2089899349 @default.
• W2885063710 cites W2100883771 @default.
• W2885063710 cites W2106533048 @default.
• W2885063710 cites W2108300554 @default.
• W2885063710 cites W2112414163 @default.
• W2885063710 cites W2120629149 @default.
• W2885063710 cites W2131862838 @default.
• W2885063710 cites W2135057615 @default.
• W2885063710 cites W2138306553 @default.
• W2885063710 cites W2146798222 @default.
• W2885063710 cites W2147338626 @default.
• W2885063710 cites W2150480709 @default.
• W2885063710 cites W2152214606 @default.
• W2885063710 cites W2153345005 @default.
• W2885063710 cites W2154625299 @default.
• W2885063710 cites W2154715694 @default.
• W2885063710 cites W2159507916 @default.
• W2885063710 cites W2164886552 @default.
• W2885063710 cites W2171484579 @default.
• W2885063710 cites W2278884777 @default.
• W2885063710 cites W2285936226 @default.
• W2885063710 cites W2466203197 @default.
• W2885063710 cites W2553392785 @default.
• W2885063710 cites W2559537906 @default.
• W2885063710 cites W2562399451 @default.
• W2885063710 cites W2578756109 @default.
• W2885063710 cites W2585095864 @default.
• W2885063710 cites W2586257925 @default.
• W2885063710 cites W2586842246 @default.
• W2885063710 cites W2587253631 @default.
• W2885063710 cites W2592236287 @default.
• W2885063710 cites W2715749014 @default.
• W2885063710 doi "https://doi.org/10.2147/cmar.s166387" @default.
• W2885063710 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6097505" @default.
• W2885063710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30147364" @default.
• W2885063710 hasPublicationYear "2018" @default.
• W2885063710 type Work @default.
• W2885063710 sameAs 2885063710 @default.
• W2885063710 citedByCount "5" @default.
• W2885063710 countsByYear W28850637102019 @default.
• W2885063710 countsByYear W28850637102020 @default.
• W2885063710 crossrefType "journal-article" @default.
• W2885063710 hasAuthorship W2885063710A5001331259 @default.
• W2885063710 hasAuthorship W2885063710A5010293813 @default.
• W2885063710 hasAuthorship W2885063710A5034997659 @default.
• W2885063710 hasAuthorship W2885063710A5039213269 @default.
• W2885063710 hasAuthorship W2885063710A5062418028 @default.
• W2885063710 hasAuthorship W2885063710A5077524239 @default.
• W2885063710 hasAuthorship W2885063710A5080003280 @default.
• W2885063710 hasBestOaLocation W28850637101 @default.
• W2885063710 hasConcept C126322002 @default.
• W2885063710 hasConcept C142724271 @default.
• W2885063710 hasConcept C143998085 @default.
• W2885063710 hasConcept C156957248 @default.
• W2885063710 hasConcept C204787440 @default.
• W2885063710 hasConcept C207103383 @default.
• W2885063710 hasConcept C27081682 @default.
• W2885063710 hasConcept C2776478404 @default.
• W2885063710 hasConcept C2778729363 @default.
• W2885063710 hasConcept C44249647 @default.
• W2885063710 hasConcept C71924100 @default.
• W2885063710 hasConcept C95190672 @default.
• W2885063710 hasConceptScore W2885063710C126322002 @default.
• W2885063710 hasConceptScore W2885063710C142724271 @default.
• W2885063710 hasConceptScore W2885063710C143998085 @default.
• W2885063710 hasConceptScore W2885063710C156957248 @default.
• W2885063710 hasConceptScore W2885063710C204787440 @default.
• W2885063710 hasConceptScore W2885063710C207103383 @default.
• W2885063710 hasConceptScore W2885063710C27081682 @default.
• W2885063710 hasConceptScore W2885063710C2776478404 @default.
• W2885063710 hasConceptScore W2885063710C2778729363 @default.
• W2885063710 hasConceptScore W2885063710C44249647 @default.
• W2885063710 hasConceptScore W2885063710C71924100 @default.
• W2885063710 hasConceptScore W2885063710C95190672 @default.
• W2885063710 hasLocation W28850637101 @default.
• W2885063710 hasLocation W28850637102 @default.

• next